Skip to main content
About the Institute
  • English
  • Français
  • Español
  • Russian

Breadcrumb

  1. Home
  2. Microbiota 9 - March 2020
  3. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section
Gastroenterology
Gynecology
Pediatrics
Dermatology

Breadcrumb

  1. Home
  2. Microbiota 9 - March 2020
  3. Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota
Gastroenterology

Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota

Autism-spectrum disorders

Commented articles

By Pr. Emmanuel Mas
Gastroenterology and Nutrition Department, Children’s Hospital, Toulouse, France

Gastroenterology
Gynecology
Pediatrics
Dermatology
  • Our publications
    • News
    • Microbiota Mag
    • Thematic folders
    • Overviews - Microbiota Magazine
  • About the Institute
    • Partnerships
    • Press room
  • Congresses
    • Congress calendar
    • Congress reviews
  • Continuing Medical Education
    • Accrediting courses
    • Xpeer App
  • Useful documents
    • Infographic
    About the Institute

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

Lay public section

Find here your dedicated section

Sources

This article is based on scientific information

Sharing is caring

Your colleagues might be interested in this topic. Why not share it?

  • Facebook
  • Twitter
  • Mail

Sections

About this article

Created 25 August 2021
Updated 05 January 2022

Commentary on the original publication by Kang et al. (Sci Rep 2019) [1]

Many studies have reported abnormal gut microbiota in individuals with Autism Spectrum Disorders (ASD), suggesting a link between gut microbiome and autismlike behaviors. Modifying the gut microbiome is a potential route to improve gastrointestinal (GI) and behavioral symptoms in children with ASD, and fecal microbiota transplant could transform the dysbiotic gut microbiome toward a healthy one by delivering a large number of commensal microbes from a healthy donor. The authors had previously performed an open-label trial of Microbiota Transfer Therapy (MTT) that combined antibiotics, a bowel cleanse, a stomach acid suppressant, and fecal microbiota transplant, and observed significant improvements in GI symptoms, autism-related symptoms, and gut microbiota. Here, the authors report on a follow-up with the same 18 participants two years after treatment was completed. Notably, most improvements in GI symptoms were maintained, and autism-related symptoms improved even more after the end of treatment. Important changes in gut microbiota at the end of treatment remained at follow-up, including significant increases in bacterial diversity and relative abundances of Bifidobacteria and Prevotella. Their observations demonstrate the long-term safety and efficacy of MTT as a potential therapy to treat children with ASD who have GI problems, and warrant a double-blind, placebo-controlled trial in the future.

What do we already know about this subject?

It is known that children with autism spectrum disorders suffer from a variety of gastrointestinal problems including constipation, diarrhea, and bloating. These children also have a dysbiotic gut microbiome characterized by an increased ratio of Firmicutes/ Bacteroidetes due to a low relative abundance of Bacteroidetes. This dysbiosis alters the gut-brain axis, promoting both the gastrointestinal problems and the characteristic autism-like behaviors. Microbiota transfer therapy consists of an initial gastrointestinal preparation with a 14 day course of vancomycin and a bowel cleanse on day 15, followed by fecal microbiota transplantation using a high initial dose of standardized human gut microbiota (by the oral or rectal route) and then a low maintenance dose for 7-8 weeks, concurrently with a proton pump inhibitor from day 12. Kang et al. previously reported that this treatment led to an 80% reduction in gastrointestinal symptoms and a smaller reduction in behavioral symptoms in children with ASD, in addition to a modification of the gut microbiota, at the 8-week follow-up.[2]

What are the main insights from this study?

This article presents a follow-up evaluation of the 18 autistic children two years after the initial microbiota transfer therapy. Improvements in gastrointestinal symptoms, as assessed by the Gastrointestinal Symptom Rating Scale questionnaire, were maintained with a 58% reduction (Figure 1). Improvements were observed in all gastrointestinal symptoms (abdominal pain, indigestion, diarrhea, and constipation). Transit remained improved, with a 26% reduction in the percentage of days of abnormal stools.

Image

The families reported that autism-related signs steadily improved. ASD severity was 47% lower than baseline when assessed by the Childhood Autism Rating Scale (Figure 2). On the Aberrant Behavior Checklist the scores continued to improve and were 35% lower at two years compared to 24 % at the 8-week follow-up. The gut microbiota was analyzed by 16S RNA analysis for 16 of the 18 children. Bacterial diversity was higher at two years than after eight weeks of follow-up (Figure 3). A higher relative abundance of Bifidobacterium and Prevotella persisted at the 2-year follow-up, while Desulfobivrio abundance did not persist significantly.

Key points

  • Microbiota transfer therapy has a persistent effect on gastrointestinal symptoms two years after the initial treatment.

  • It also has an effect on autism behaviors two years after the initial treatment.

  • Further research is needed to determine whether microbiota transfer could improve autism behaviors even in the absence of gastrointestinal problems.

What are the consequences in practice?

These findings indicate that microbiota transfer therapy has a durable, long-term effect on the gut microbiota. In addition, it significantly and durably improves gastrointestinal and behavioral symptoms of autism spectrum disorders. It is now essential to carry out randomized, controlled, double-blind studies in children with ASD who do or do not have gastrointestinal problems. Indeed, dysbiosis may be present and impact the gut-brain axis even in the absence of gastrointestinal symptoms. The results of this study should be confirmed before this approach is used in clinical practice.

Image

Conclusion

This study confirms the benefits of microbiota transfer therapy in children with autism spectrum disorders. The effects of the initial treatment were maintained at the 2-year follow-up on both the gut microbiota and on gastrointestinal symptoms, with even a continued improvement in autism-like behaviors.

Sources

1 Kang DW, Adams JB, Coleman DM, et al. Long-term benefit of Microbiota Transfer Therapy on autism symptoms and gut microbiota. Sci Rep 2019 ; 9 : 5821.

2 Kang DW, Adams JB, Gregory AC, et al. Microbiota Transfer Therapy alters gut ecosystem and improves gastrointestinal and autism symptoms: an open-label study. Microbiome 2017 ; 5 : 10.

Tags
Gastroenterology Pediatrics Psychiatry Fecal transplant Gut-brain axis Children health

en_view en_sources

    Focus
    Microbiota 9 - March 2020
    • Overview
      • Impact of antibiotics on the gut microbiota, does it matter?
    • Commented articles
      • Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease
      • Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota
    • Congress review
      • UEG Week 2019 - Intestinal microbiota: influencing factors and role in certain pathologies
      • ADPW 2019: The growing importance of gut microbiota on digestive health
    • Press review
      • Implication of vaginal microbiota in bacterial vaginosis and candidiasis
      • Skin microbiota : which role in atopic dermatitis and acne?
      • Modulating gut microbiota in metabolism disorders and alcoholic hepatitis
    Created 25 August 2021
    Updated 05 January 2022

    About this article

    To know more about this topic.

    Main topic

    Autism-spectrum disorders

    Content type

    Commented article
    Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease
    UEG Week 2019 - Intestinal microbiota: influencing factors and role in certain pathologies
    Focus

    Microbiota 9 - March 2020

    Overview

    Impact of antibiotics on the gut microbiota, does it matter?

    Commented articles

    Whole-virome analysis sheds light on viral dark matter in inflammatory bowel disease Long-term benefit of microbiota transfer therapy on autism symptoms and gut microbiota

    Congress review

    UEG Week 2019 - Intestinal microbiota: influencing factors and role in certain pathologies ADPW 2019: The growing importance of gut microbiota on digestive health

    Press review

    Implication of vaginal microbiota in bacterial vaginosis and candidiasis Skin microbiota : which role in atopic dermatitis and acne? Modulating gut microbiota in metabolism disorders and alcoholic hepatitis

    Continue reading

    News
    22.11.2021

    Irritable bowel syndrome: is fecal microbiota transplantation effective in the long term?

    Read the article
    WMD_Foundation KOL Mexico 2019
    10.06.2022

    Pr. Moisés Alvarez (Mexican winner 2019): Microbiota & colorectal cancer

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article
    WMD_Foundation KOL USA 2021
    16.06.2022

    Dr. Queen (USA winner 2020): Microbiota & colorectal cancer

    Read the article
    WMD_Foundation KOL USA 2022
    16.06.2022

    Dr. Brown (USA winner 2021): Microbiota & respiratory syncitial virus infection

    Read the article
    31.05.2022

    Pr. Maslennikov (Russian winner 2019): Probiotics & cirrhosis

    Read the article
    WMD_Foundation KOL Russia 2020
    15.06.2022

    Pr. Shifrin (Russian winner 2020): Gut microbiota & antibiotics

    Read the article
    WMD_Foundation KOL Russia 2021
    15.06.2022

    Pr. Volynets (Russian winner 2021): Gut microbiota & hepatobiliary chronic diseases

    Read the article
    What's worth reading about microbiota
    Follow us on Twitter
    Read our thematic folder
    The Janus face of Antibiotics: Life Savers & Microbiota Disrupters
    NL13_cover
    Check out latest newsletter
    IBS, Microbiota & Covid-19
    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section
    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology
    • English
    • Français
    • Español
    • Russian

    Browse the site

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    Lay public section

    Find here your dedicated section

    Redirection

    You are about to be redirected and leave our website

    • Be redirected
    • Stay on the Biocodex Microbiota Institute's website

    Stay with us !

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    Explore

    Photo: Postménopause : l'action bénéfique de l'estradiol sur le microbiote vaginal
    22.06.2022

    Postmenopause: the beneficial action of estradiol on the vaginal microbiota

    Read the article
    WMD_Foundation KOL USA 2018
    17.06.2022

    Dr. Yang (USA winner 2018): Gut microbiota & gut brain axis

    Read the article
    WMD_Foundation KOL USA 2017
    17.06.2022

    Dr. Singh (USA winner 2017): Microbiota & polyphenols

    Read the article

    Stay updated

    Join the Microbiota Community of HCPs and researchers and receive once a month the “Microbiota Digest” to stay up to date on the latest news about microbiota.

    * Mandatory Fields

    BMI 20-35

    • Our publications
      • News
      • Microbiota Mag
      • Thematic folders
      • Overviews - Microbiota Magazine
    • About the Institute
      • Partnerships
      • Press room
    • Congresses
      • Congress calendar
      • Congress reviews
    • Continuing Medical Education
      • Accrediting courses
      • Xpeer App
    • Useful documents
      • Infographic
      About the Institute

      Join the microbiota community

      • Facebook
      • Twitter
      • YouTube

    Lay public section

    Find here your dedicated section

    Discover

    Gastroenterology
    Gynecology
    Pediatrics
    Dermatology

    Lay public section

    Find here your dedicated section

    Join the microbiota community

    • Facebook
    • Twitter
    • YouTube

    © 2022 Biocodex. All rights reserved.

    • Cookies Policy
    • Data protection policy
    • GTU
    • Sitemap
    • Cookies settings
    Biocodex logo